Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders

Abstract

Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.

1 - 96 . (canceled)  
   
   
       97 . A composition comprising synergistic effective amounts of an anti-diabetic agent other than insulin, a bioavailable source of chromium, and a bioavailable source of vanadium, wherein said anti-diabetic agent selected from the group consisting of glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), analogues of GLP-1, analogues of GLP-2, agonists of the GLP-1 receptor, and agonists of the GLP-2 receptor, and wherein components of said composition synergistically reduce the HbA1c levels of a patient by at least about 10% after treatment for a period of at least about thirty days with said composition as compared to treatment with said anti-diabetic agent alone.  
   
   
       98 . The composition of  claim 97 , wherein said anti-diabetic agent is selected from the group consisting of glucagon-like peptide 1 (GLP-1), analogues of GLP-1, and agonists of the GLP-1 receptor.  
   
   
       99 . The composition of  claim 97 , wherein said reduction in said Hb1Ac level is at least about 50%.  
   
   
       100 . The composition of  claim 97 , wherein said bioavailable source of chromium comprises one or more of chromium picolinate or chromium polynicotinate.  
   
   
       101 . The composition according to  claim 100 , wherein the bioavailable source of chromium is chromium picolinate and wherein the amount of chromium picolinate is from about 30 μg up to about 1000 μg, per dose.  
   
   
       102 . The composition according to  claim 100 , wherein the bioavailable source of chromium is chromium polynicotinate and wherein the amount of chromium polynicotinate is from about 30 μg up to about 5000 μg, per dose.  
   
   
       103 . The composition of  claim 97 , wherein said bioavailable source of chromium comprises no less than about 200 micrograms of elemental chromium.  
   
   
       104 . The composition of  claim 97 , wherein said bioavailable source of chromium comprises no less than about 100 micrograms of elemental chromium.  
   
   
       105 . The composition of  claim 97 , wherein said bioavailable source of chromium comprises no less than about 5 micrograms of elemental chromium.  
   
   
       106 . The composition of  claim 97 , wherein said bioavailable source of vanadium is vanadyl sulfate.  
   
   
       107 . The composition of  claim 106 , wherein the amount of vanadyl sulfate is in the range of about 20 mg up to about 100 mg, per dose.  
   
   
       108 . The composition of  claim 97 , wherein said bioavailable source of vanadium comprises more than about 10 mg elemental vanadium.  
   
   
       109 . The composition of  claim 97 , wherein said amount of said bioavailable source of vanadium comprises no less than 5 mg of elemental vanadium.  
   
   
       110 . The composition according to  claim 97 , wherein said anti-diabetic agent is GLP-1.  
   
   
       111 . The composition according to  claim 97 , wherein said anti-diabetic agent is an analogue of GLP-1.  
   
   
       112 . The composition according to  claim 97 , wherein said anti-diabetic agent is an agonist of the GLP-1 receptor.  
   
   
       113 . The composition of  claim 100  wherein said anti-diabetic agent is selected from the group consisting of GLP-1, analogues of GLP-1, and agonists of the GLP-1 receptor.  
   
   
       114 . The composition according to  claim 100 , wherein said anti-diabetic agent is GLP-1.  
   
   
       115 . The composition according to  claim 100 , wherein said anti-diabetic agent is an analogue of GLP-1.  
   
   
       116 . The composition according to  claim 100 , wherein said anti-diabetic agent is an agonist of the GLP-1 receptor.  
   
   
       117 . The composition of  claim 106  wherein said anti-diabetic agent is selected from the group consisting of GLP-1, analogues of GLP-1, and agonists of the GLP-1 receptor.  
   
   
       118 . The composition according to  claim 106 , wherein said anti-diabetic agent is GLP-1.  
   
   
       119 . The composition according to  claim 106 , wherein said anti-diabetic agent is an analogue of GLP-1.  
   
   
       120 . The composition according to  claim 106 , wherein said anti-diabetic agent is an agonist of the GLP-1 receptor.  
   
   
       121 . A method for improving glucose metabolism, comprising treating a patient for at least about a thirty day period by administering a pharmaceutical composition comprising synergistic effective amounts of an anti-diabetic agent other than insulin, a bioavailable source of chromium, and a bioavailable source of vanadium, wherein said anti-diabetic agent is selected from the group consisting of glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), analogues of GLP-1, analogues of GLP-2, agonists of the GLP-1 receptor, and agonists of the GLP-2 receptor, and wherein said components of said composition synergistically reduce the HbA1c level of said patient by at least about 10% after such treatment as compared to treatment with said anti-diabetic agent alone.  
   
   
       122 . The method of  claim 121 , wherein said anti-diabetic agent is selected from the group consisting of glucagon-like peptide 1 (GLP-1), analogues of GLP-1, and agonists of the GLP-1 receptor.  
   
   
       123 . The method of  claim 121 , wherein said bioavailable source of chromium comprises no less than about 200 micrograms elemental chromium when said composition is administered on a daily basis.  
   
   
       124 . The method of  claim 121 , wherein said bioavailable source of chromium comprises no less than about 5 micrograms of elemental chromium when said composition is administered on a daily basis.  
   
   
       125 . The method of  claim 121 , wherein said bioavailable source of chromium comprises one or more of chromium picolinate or chromium polynicotinate.  
   
   
       126 . The method of  claim 125 , wherein said anti-diabetic agent is selected from the group consisting of GLP-1, analogues of GLP-1, and agonists of the GLP-1 receptor.  
   
   
       127 . The method of  claim 125 , wherein said anti-diabetic agent is GLP-1.  
   
   
       128 . The method of  claim 125 , wherein said anti-diabetic agent is an analogue of GLP-1.  
   
   
       129 . The method of  claim 125 , wherein said anti-diabetic agent is an agonist of the GLP-1 receptor.  
   
   
       130 . The method of  claim 121 , wherein said bioavailable source of vanadium comprises at least about 10 mg elemental vanadium when said composition is administered on a daily basis.  
   
   
       131 . The method of  claim 121 , wherein said bioavailable source of vanadium comprises at least about 5 mg of elemental vanadium when said composition is administered on a daily basis.  
   
   
       132 . The method of  claim 121 , wherein said bioavailable source of vanadium is vanadyl sulfate.  
   
   
       133 . The method of  claim 132 , wherein said anti-diabetic agent is selected from the group consisting of GLP-1, analogues of GLP-1, and agonists of the GLP-1 receptor.  
   
   
       134 . The composition according to  claim 132 , wherein said anti-diabetic agent is GLP-1.  
   
   
       135 . The method of  claim 132 , wherein said anti-diabetic agent is an analogue of GLP-1.  
   
   
       136 . The method of  claim 132 , wherein said anti-diabetic agent is an agonist of the GLP-1 receptor.  
   
   
       137 . The method of  claim 121 , wherein said pharmaceutical composition further comprises a physiologically acceptable carrier.  
   
   
       138 . The method of  claim 121 , wherein said method further comprises monitoring said subject's HbA1c levels.  
   
   
       139 . The method of  claim 121 , wherein said reduction in said Hb1Ac level is at least about 50%.